SCHEMBL5542201

SCHEMBL5542201

FC(F)(F)c1ccccc1-c1[c]coc1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 1/20 0.44
NOTUM Q6P988 2/20 0.41
HSD11B1 P28845 5/20 0.39
PSMB8 P28062 1/20 0.37
ALDH1A1 P00352 2/20 0.35
HPGD P15428 1/20 0.35
AR P10275 1/20 0.35
C1R P00736 1/20 0.35
CNR2 P34972 1/20 0.33
SLC9A1 P19634 1/20 0.33
AKR1C3 P42330 1/20 0.33
AKR1C2 P52895 1/20 0.33
LMNA P02545 1/20 0.33
POLB P06746 1/20 0.33
GAA P10253 1/20 0.33
NPFFR1 Q9GZQ6 1/20 0.33
NPFFR2 Q9Y5X5 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5536155 0.72 CYP2A6 (0.40) NOTUMHSD11B1ALDH1A1HPGDLMNA
SCHEMBL5376166 0.72 ALDH1A1 (0.40) ALDH1A1HPGDC1RLMNAGAA
SCHEMBL1369845 0.72 HSD11B1 (0.42) SCN9ANOTUMHSD11B1PSMB8ALDH1A1
SCHEMBL197671 0.71 HSD11B1 (0.56) NOTUMHSD11B1PSMB8ALDH1A1HPGD
SCHEMBL1222023 0.70 NOTUM (0.42) SCN9ANOTUMHSD11B1PSMB8ALDH1A1
Hydrochloric Acid SCHEMBL29010139 0.69 HSD11B1 (0.54) NOTUMHSD11B1PSMB8ALDH1A1HPGD
SCHEMBL8022901 0.69 HSD11B1 (0.54) NOTUMHSD11B1PSMB8ALDH1A1HPGD
SCHEMBL5534450 0.67 KDM1A (0.36) HSD11B1ALDH1A1
SCHEMBL5547861 0.67 KIF11 (0.42) NOTUMALDH1A1
SCHEMBL5778162 0.67 HSD11B1 (0.38) SCN9ANOTUMHSD11B1PSMB8ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 SCN9A 3612/4885NOTUM 3827/4885HSD11B1 256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.